Gene · 8081
Papers1,614
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,614
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A mechanistic model for recombinant adeno-associated virus production dynamics in a helper virus-assisted producer cell line. | Biotechnol Prog | 2026 | 42244226 | PubTator, text mining | PubMed |
| An Ad5-vectored platform generating self-assembling VLPs elicits potent mucosal immunity against influenza A virus and SARS-CoV-2. | Proc Natl Acad Sci U S A | 2026 | 42054358 | PubTator, text mining | PubMed |
| Progress in the research and development of oncolytic virus therapies. | Front Pharmacol | 2026 | 41800095 | PubTator, text mining | PubMed |
| Development and psychometric validation of caring leadership scale in nursing. | PLoS One | 2026 | 41770765 | PubTator, text mining | PubMed |
| Differential assembly of RNP granules via activation of distinct dsRNA sensors by adenovirus mutants. | bioRxiv | 2026 | 41756847 | PubTator, text mining | PubMed |
| Combination of oncolytic viruses and immune checkpoint inhibitors for treatment of high-grade gliomas. | Front Neurol | 2026 | 41756179 | PubTator, text mining | PubMed |
| Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/SPAM1-armed oncolytic adenovirus Ad5Δ24RGD. | Mol Ther Oncol | 2026 | 41716467 | PubTator, text mining | PubMed |
| Sex Differences in Response to Viral Vector Vaccines-Implications for Future Vaccine Design. | Immunol Rev | 2026 | 41612856 | PubTator, text mining | PubMed |
| Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials. | Vaccines (Basel) | 2025 | 40266233 | PubTator, text mining | PubMed |
| Chimeric Ad5/35 oncolytic adenovirus overcome preexisting neutralizing antibodies and enhance tumor targeting efficiency. | Cancer Gene Ther | 2025 | 40057574 | PubTator, text mining | PubMed |
| New approach methodologies to assess wanted and unwanted drugs-induced immunostimulation. | Curr Res Toxicol | 2025 | 40027547 | PubTator, text mining | PubMed |
| Bridging gene therapy and next-generation vaccine technologies. | Gene Ther | 2025 | 39558149 | PubTator, text mining | PubMed |
| Transcriptomics-informed pharmacology identifies epigenetic and cell cycle regulators that enhance AAV production. | Mol Ther Methods Clin Dev | 2024 | 39687728 | PubTator, text mining | PubMed |
| FastAd: A versatile toolkit for rapid generation of single adenoviruses or diverse adenoviral vector libraries. | Mol Ther Methods Clin Dev | 2024 | 39559559 | PubTator, text mining | PubMed |
| Structure-derived insights from blood factors binding to the surfaces of different adenoviruses. | Nat Commun | 2024 | 39528527 | PubTator, text mining | PubMed |
| Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023. | Sci Rep | 2024 | 39427003 | PubTator, text mining | PubMed |
| The Expression and Function of the Small Nonstructural Proteins of Adeno-Associated Viruses (AAVs). | Viruses | 2024 | 39205189 | PubTator, text mining | PubMed |
| Designing efficient materials for high-performance of non-fullerene organic solar cells through side-chain engineering on DBT-4F derivatives by non-fused-ring electron acceptors. | J Mol Model | 2024 | 38809306 | PubTator, text mining | PubMed |
| A causal multiomics study discriminates the early immune features of Ad5-vectored Ebola vaccine recipients. | Innovation (Camb) | 2024 | 38745762 | PubTator, text mining | PubMed |
Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study. | Emerg Microbes Infect | 2024 | 38678636 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8081/papers